Pmv Pharmaceuticals Inc (PMVP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pmv Pharmaceuticals Inc (PMVP) has a cash flow conversion efficiency ratio of -0.164x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.82 Million) by net assets ($121.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Pmv Pharmaceuticals Inc balance sheet quality to measure how much of total assets are equity-financed.
Pmv Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Pmv Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Pmv Pharmaceuticals Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Pmv Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pmv Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
JCBNext Berhad Bhd
KLSE:0058
|
0.006x |
|
ZENTEK LTD.
F:ZAY0
|
-0.158x |
|
Camus Engineering & Construction Inc
KO:013700
|
0.037x |
|
Trek Metals Ltd
AU:TKM
|
-0.027x |
|
Shanghai Yaohua Pilkington Glass Group Co Ltd B
SHG:900918
|
0.039x |
|
GreenMobility A/S
CO:GREENM
|
0.802x |
|
Aplex Technology
TWO:6570
|
0.044x |
|
Ak Holdings
KO:006840
|
0.117x |
Annual Cash Flow Conversion Efficiency for Pmv Pharmaceuticals Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Pmv Pharmaceuticals Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Pmv Pharmaceuticals Inc (PMVP) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $104.71 Million | $-73.58 Million | -0.703x | -141.26% |
| 2024-12-31 | $176.08 Million | $-51.28 Million | -0.291x | -18.10% |
| 2023-12-31 | $225.69 Million | $-55.66 Million | -0.247x | +4.84% |
| 2022-12-31 | $246.03 Million | $-63.76 Million | -0.259x | -71.71% |
| 2021-12-31 | $308.56 Million | $-46.57 Million | -0.151x | -65.56% |
| 2020-12-31 | $359.12 Million | $-32.74 Million | -0.091x | -129.12% |
| 2019-12-31 | $-70.47 Million | $-22.07 Million | 0.313x | -4.82% |
| 2018-12-31 | $-46.14 Million | $-15.18 Million | 0.329x | -- |
About Pmv Pharmaceuticals Inc
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as … Read more